Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets - 06/10/15

Abstract |
Background |
Identifying differences and similarities between cutaneous lymphocyte antigen (CLA)+ polarized T-cell subsets in children versus adults with atopic dermatitis (AD) is critical for directing new treatments toward children.
Objective |
We sought to compare activation markers and frequencies of skin-homing (CLA+) versus systemic (CLA−) “polar” CD4 and CD8 T-cell subsets in patients with early pediatric AD, adults with AD, and control subjects.
Methods |
Flow cytometry was used to measure CD69/inducible costimulator/HLA-DR frequency in memory cell subsets, as well as IFN-γ, IL-13, IL-9, IL-17, and IL-22 cytokines, defining TH1/cytotoxic T (TC) 1, TH2/TC2, TH9/TC9, TH17/TC17, and TH22/TC22 populations in CD4 and CD8 cells, respectively. We compared peripheral blood from 19 children less than 5 years old and 42 adults with well-characterized moderate-to-severe AD, as well as age-matched control subjects (17 children and 25 adults).
Results |
Selective inducible costimulator activation (P < .001) was seen in children. CLA+ TH2 T cells were markedly expanded in both children and adults with AD compared with those in control subjects, but decreases in CLA+ TH1 T-cell numbers were greater in children with AD (17% vs 7.4%, P = .007). Unlike in adults, no imbalances were detected in CLA− T cells from pediatric patients with AD nor were there altered frequencies of TH22 T cells within the CLA+ or CLA− compartments. Adults with AD had increased frequencies of IL-22–producing CD4 and CD8 T cells within the skin-homing population, compared with controls (9.5% vs 4.5% and 8.6% vs 2.4%, respectively; P < .001), as well as increased HLA-DR activation (P < .01).
Conclusions |
These data suggest that TH2 activation within skin-homing T cells might drive AD in children and that reduced counterregulation by TH1 T cells might contribute to excess TH2 activation. TH22 “spreading” of AD is not seen in young children and might be influenced by immune development, disease chronicity, or recurrent skin infections.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, T cell, cutaneous lymphocyte antigen, IL-13, IL-22, IFN-γ, inducible costimulator, CD69, HLA-DR
Abbreviations used : AD, CLA, ICOS, PE, PMA, TC, TCM, TEM
Plan
| Supported by a research grant from the LEO Foundation (research grant no. 0266-2572, GCO no. 13-1310 to E.-G.-Y. and A.S.P.). T.C. was cosponsored by the Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust. J.G. was supported in part by grant no. UL1TR0000 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. D.M. received funding from the American Dermatological Association Medical Student Fellowship. J.G.K. was supported by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Blood acquisition was supported by the Northwestern University Skin Disease Research Center (NIAMS P30AR057216). |
|
| Disclosure of potential conflict of interest: J. G. Krueger reports that money was paid to his institution by and/or he has received personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter, Parexel, Xenoport, and Kineta. A. S. Paller has received research support from the LEO Foundation; has received consultancy fees from Abbvie, Anacor, Celsus, Chugai Pharma, Galderma, GSK-Stiefel, Novartis, and Promius Pharma; and is an investigator for Abbvie. E. Guttman-Yassky is a board member for Sanofi Aventis, Regeneron, Stiefel/GSK, Medimmune, Celgene, Anacor, and Leo Pharma; has received consultancy fees from Regeneron, Sanofi Aventis, Medimmune, Celgene, Steifel/GSK, Celsus, BMS, Amgen, and Drais; and has received research support from Regeneron, Celgene, BMS, and Janssen. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 136 - N° 4
P. 941 - octobre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
